Sajid Mirza, MD
Advanced Heart Failure and Transplant Cardiology · Atlantis, FLNPI 1720354921
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,684 of the $10,204 with a category attached, or 75.3%. 30 manufacturers reported payments, led by Abbott at 39.1% of the total. Reporting peaked in 2022 at $2,155 and has fallen 61.1% since, to $839 in 2025.
Across 236 payments — averaging $43.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Abiomed$1K
- United Therapeutics Corporation$631
- Actelion Pharmaceuticals US, Inc.$616
- Bayer$401
- Alnylam Pharmaceuticals Inc.$387
- plus $3K from 24 others
What the payments were for
- Consulting fees$6757%
- Travel & lodging$1,72917%
- Food & beverage$7,68475%
- Education$1161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 58 | $3,991 |
| Abiomed | 15 | $1,403 |
| United Therapeutics Corporation | 23 | $631 |
| Actelion Pharmaceuticals US, Inc. | 18 | $616 |
| Bayer | 15 | $401 |
| Alnylam Pharmaceuticals Inc. | 11 | $387 |
| Cvrx, Inc. | 5 | $361 |
| Novartis | 18 | $350 |
| Impulse Dynamics (USA) Inc. | 4 | $280 |
| Boehringer Ingelheim | 7 | $233 |
| AstraZeneca | 11 | $220 |
| Kestra Medical Technology Services, Inc. | 2 | $175 |
| Boston Scientific | 3 | $150 |
| Pfizer | 7 | $150 |
| Medtronic(2 entities) | 5 | $117 |
| E.r. Squibb & Sons, L.L.C. | 4 | $112 |
| Akcea Therapeutics, Inc. | 4 | $95 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $91 |
| Bridgebio Pharma, Inc. | 4 | $91 |
| Merck | 2 | $61 |
| Scpharmaceuticals Inc. | 2 | $44 |
| Vifor Pharma, Inc. | 2 | $42 |
| Lexicon Pharmaceuticals, Inc. | 2 | $41 |
| Biosense Webster, Inc. | 1 | $29 |
| Amgen | 1 | $29 |
| Endotronix, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $24 |
| Heartflow, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Sobi, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HeartMate PHP$1,390
- Impella$1,015
- CARDIOMEMS$904
- OPTIMIZER$342
- Barostim Neo System$276
- CardioMEMS HF System$216
- Mitra Clip system$148
- AMVUTTRA$122
- REMODULIN$111
- Assure WCD$107
- JARDIANCE$102
How this compares
$10,204 in reported general payments places this provider in the 60th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 61 | $1,757,584 |
| Tyvaso DpiTreprostinil | 33 | $805,633 |
| CamzyosMavacamten | 62 | $514,711 |
| AdempasRiociguat | 34 | $480,651 |
| UptraviSelexipag | 14 | $373,389 |
| OpsumitMacitentan | 13 | $159,557 |
| Orenitram ErTreprostinil Diolamine | 12 | $103,078 |
| JardianceEmpagliflozin | 41 | $55,506 |
| EntrestoSacubitril/Valsartan | 39 | $54,408 |
| EliquisApixaban | 27 | $33,772 |
| FarxigaDapagliflozin Propanediol | 21 | $28,701 |
| Eplerenone | 12 | $1,169 |
| Spironolactone | 62 | $790 |
| Metoprolol Succinate | 28 | $593 |
| Torsemide | 25 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $150 | $1,791,35688 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $616 | $532,94627 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $112 | $514,71162 claims |
| BayerAdempas | $401 | $480,65134 claims |
| Boehringer IngelheimJardiance | $233 | $55,50641 claims |
| NovartisEntresto | $350 | $54,40839 claims |
| AstraZenecaFarxiga | $220 | $28,70121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Atlantis
- Waqas GhummanAtlantis$276K
- Tiffany Graham-MooreAtlantis$988
- Kelly McCantsWinter Park$445K
- Naveen BellamOrlando$414K
- Phillip HabibDelray Beach$305K
- David SnipeliskyWeston$250K
- Elsy NavasNaples$234K
- David BaranWeston$116K
- Rohan GoswamiJacksonville$112K
- Tara Hrobowski-BlackmanLargo$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.